What it is
Pancragen is a tetrapeptide — a peptide made of exactly four amino acids — derived from the pancreas, the organ behind the stomach that makes both insulin and digestive enzymes.
Its amino acid sequence matches that of natural regulator peptides found in the pancreas, and that match is what lets it target pancreatic cells specifically. Once there, it is described as normalising protein production and improving how well both halves of the pancreas work: the endocrine part, which secretes insulin into the blood, and the exocrine part, which produces the enzymes that digest food.
That is a bioregulator's way of working. Bioregulators are much shorter peptides than most on this site, and their small size means less for the immune system to react against, lowering the chance of an unwanted immune response. Rather than signalling to a cell from outside — where the effect stops once the peptide clears — each bioregulator is tied to one tissue, binds to DNA in that tissue's cells, and changes which genes are switched on. Since those genes govern repair, regeneration, and ageing, the effects are presented as more foundational and longer-lasting than those of a standard peptide.
The research interest is in regulating pancreatic function and supporting metabolic homeostasis — the body's ability to keep things like blood sugar within a steady range — particularly where glucose metabolism or the structure of the pancreas is affected.
It comes as a dry powder in a 20 milligram vial, mixed with bacteriostatic water and injected just under the skin.
Pancragen is a pancreas-derived tetrapeptide bioregulator whose sequence corresponds to endogenous pancreatic regulatory peptides, described as targeting pancreatic cells, normalising protein synthesis, and improving functional activity of both endocrine and exocrine compartments.
The targeting mechanism claimed here is more concrete than the generic class account, and the sequence correspondence is the reason. Because the tetrapeptide reproduces sequences found in the pancreas's own regulatory peptides, it is described as recognised by pancreatic cells specifically — that is the tissue specificity the class rests on, given a chemical basis rather than merely asserted. What follows is the standard claim: the compound acts on DNA inside those cells and sets which genes they express, rather than delivering a signal from outside that lapses when the molecule clears. Because the genes in question are those of repair, regeneration, and longevity, the effect is presented as persisting past the course. The four-residue length is separately credited with keeping immunogenicity low. No gene target is named and no binding data are offered.
Stated research positioning is regulation of pancreatic function and support of metabolic homeostasis, particularly in conditions affecting glucose metabolism and pancreatic integrity.
What distinguishes this compound among the bioregulators on this site is that its interaction profile is pharmacologically substantive rather than generic: increased sensitivity to insulin, metformin, GLP-based medications, and SGLT2 inhibitors. That is a hypoglycaemia consideration in a population likely already on those agents, and it is the single most actionable item here.
Presentation: 20 mg lyophilised vial, reconstituted with bacteriostatic water, subcutaneous, on cycles of 20–60 days with daily or alternate-day dosing depending on protocol.
What it does
The core effects are metabolic. Pancragen modulates insulin secretion and glucose metabolism, and improves insulin sensitivity — how readily the body's cells respond to insulin, which is the thing that declines in type 2 diabetes.
On the pancreas itself: it supports pancreatic health and the regeneration of islet cells, the clusters of cells that produce insulin. It reduces oxidative stress and inflammation in pancreatic cells, and improves how the pancreas responds to metabolic stress or injury. It speeds recovery after pancreatitis — inflammation of the pancreas — or other pancreatic disorders.
On digestion: it normalises the secretion of digestive enzymes, and improves both how well nutrients are absorbed and the balance of those enzymes.
Two of the claims are stronger and deserve naming separately. Pancragen is said to be helpful in reducing tolerance to GLP medications — the weight-loss and diabetes drugs that copy a gut hormone called glucagon-like peptide-1, the class including semaglutide and tirzepatide — with tolerance meaning the effect of those drugs fading over time. And it is called the best option for preventing, reducing, or reversing diabetic complications, naming diabetic neuropathy (nerve damage caused by diabetes) and vascular dysfunction. That is the most emphatic claim made for it, and there is no evidence to support it.
Metabolic actions: modulation of insulin secretion and glucose metabolism, and improved insulin sensitivity.
Pancreatic: support for pancreatic health and islet cell regeneration; reduced oxidative stress and inflammation in pancreatic cells; enhanced pancreatic response to metabolic stress or injury; accelerated recovery following pancreatitis or other pancreatic disorders.
Exocrine: normalisation of digestive enzyme secretion; improved nutrient assimilation and pancreatic enzyme balance.
Two claims are substantially stronger than the rest and should be flagged as such. First, that Pancragen is helpful in reducing tolerance to GLP-based medications — a pharmacodynamic tolerance claim about a widely prescribed drug class, made without supporting data. Second, that it is the best option to prevent, mitigate, or reverse diabetic complications including diabetic neuropathy and vascular dysfunction. That is a superlative therapeutic claim about microvascular and neuropathic complications of diabetes, and no evidence supports it. Both should be read as marketing register rather than evidence.
The interaction profile bears directly on the metabolic claims: increased sensitivity to insulin, metformin, GLP medications, and SGLT2 inhibitors is stated explicitly. If the insulin-sensitivity effect is real in someone on glucose-lowering therapy, hypoglycaemia is the foreseeable consequence, and no monitoring guidance has been established.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Modulates insulin secretion and glucose metabolism.Animal or lab only
- Described as helpful in reducing tolerance to GLP medications, where their effect fades over time.Anecdotal
- Described as the best option to prevent, reduce, or reverse diabetic complications, including diabetic nerve damage and blood vessel dysfunction. This is the strongest claim made for it, and there is no evidence to back it up.Anecdotal
- Reduces oxidative stress and inflammation in pancreatic cells.Animal or lab only
- Supports pancreatic health and the regeneration of islet cells, the clusters that produce insulin.Animal or lab only
- Speeds recovery following pancreatitis or other pancreatic disorders.Anecdotal
- Improves insulin sensitivity — how readily the body's cells respond to insulin.Anecdotal
- Improves how the pancreas responds to metabolic stress or injury.Anecdotal
- Normalises the secretion of digestive enzymes.Anecdotal
- Improves how well nutrients are absorbed, and the balance of pancreatic enzymes.Anecdotal
- Modulates insulin secretion and glucose metabolism.Animal or lab only
- Stated as helpful in reducing tolerance to GLP medications — a pharmacodynamic tolerance claim made without supporting data.Anecdotal
- Stated as the best option to prevent, mitigate, or reverse diabetic complications including diabetic neuropathy and vascular dysfunction. A superlative claim, unsupported by evidence.Anecdotal
- Reduces oxidative stress and inflammation in pancreatic cells.Animal or lab only
- Supports pancreatic health and islet cell regeneration.Animal or lab only
- Accelerates recovery following pancreatitis or other pancreatic disorders.Anecdotal
- Improves insulin sensitivity.Anecdotal
- Enhances pancreatic response to metabolic stress or injury.Anecdotal
- Normalises digestive enzyme secretion.Anecdotal
- Improves nutrient assimilation and pancreatic enzyme balance.Anecdotal
Reconstitution and dosing
The vial holds 20 milligrams (mg). Mix it with 2 millilitres (mL) of bacteriostatic water. On an insulin syringe that is the 200 mark, because 100 units is 1 mL. Add the water slowly down the inside wall of the vial rather than onto the powder, then swirl gently. Do not shake. Both protocols use the same amount of water.
With 20 mg in 2 mL, every unit on the syringe holds 100 micrograms. So 2 milligrams is 20 units.
Inject under the skin. The dose is the same in both protocols — 2 milligrams — and it does not ramp up or down. What changes is how often and for how long.
The standard protocol is every day for 20 to 30 days. The extended protocol is every other day for 40 to 60 days. Those work out to roughly the same total amount of peptide: 20 to 30 doses either way. The extended version simply spreads it over twice as long.
Overall, a cycle runs 20 to 60 days, with two or three cycles a year.
No dosing time or relationship to food has been established. Given that the compound affects blood sugar and digestive enzymes, and that meals affect both, that is a significant omission.
Presentation: 20 mg vial reconstituted with 2 mL (200 units) of bacteriostatic water, giving 10 mg/mL — 100 mcg per insulin unit. Same diluent volume for both protocols. Add down the vial wall and swirl; do not shake.
Recomputed draw: 2 mg = 20 units. The single dose level across both protocols carries no discrepancy.
Administration: subcutaneous. Dose is flat at 2 mg in both protocols with no titration; the protocols differ only in frequency and duration.
Standard protocol: 2 mg daily for 20–30 days. Extended protocol: 2 mg every other day for 40–60 days. Cumulative exposure is near-identical — 20–30 administrations, i.e. 40–60 mg, two to three vials — with the extended schedule distributing the same total over twice the elapsed time. No criterion for choosing between them has been established.
Cycle: 20–60 days, 2–3 cycles per year.
No dosing time or meal relationship is stated, which is a material omission for a compound whose stated actions are insulin secretion, glucose metabolism, and digestive enzyme secretion — all postprandially modulated. Several sibling bioregulator entries on this site specify bedtime dosing at a fixed postprandial interval; this one specifies nothing.
Also absent: any glucose monitoring guidance, despite the stated potentiation of insulin, metformin, GLP agents, and SGLT2 inhibitors.
20 mg vial — standard protocol (20–30 days)
Mix with 2 mL (200 units) of BAC water, giving 10 mg/mL — 100 mcg per insulin unit.
10 mg/mL · 100 mcg per unit
Cycle: 20–30 days; 2 or 3 cycles per year · Frequency: 1×/day, every day; subcutaneous. No dosing time or relationship to meals has been established
| When | Dose | Draw | How often |
|---|---|---|---|
| Every day for 20–30 days (2 mg) | 2 mg | 20 units | 1×/day |
20 mg vial — extended protocol (40–60 days)
Mix with 2 mL (200 units) of BAC water, giving 10 mg/mL — 100 mcg per insulin unit.
10 mg/mL · 100 mcg per unit
Cycle: 40–60 days; 2 or 3 cycles per year · Frequency: Every other day; subcutaneous. No dosing time or relationship to meals has been established
| When | Dose | Draw | How often |
|---|---|---|---|
| Every other day for 40–60 days (2 mg) | 2 mg | 20 units | 1× on dosing days |
20 mg in 2 mL is 10 mg/mL, or 100 mcg per unit. Draw 20 units (0.2 mL) for 2000 mcg.
Who should avoid it
- Anyone pregnant or breastfeeding. This is an absolute exclusion.
- Anyone with severe acute pancreatitis — a sudden, serious inflammation of the pancreas. Also an absolute exclusion.
- Anyone with active pancreatic cancer. Also an absolute exclusion.
- Anyone with uncontrolled diabetes, especially type 1, should only use it under supervision from a medical professional. This is a separate category from the absolute exclusions above.
- Anyone with kidney or liver failure — again, only under medical supervision.
- Anyone with an autoimmune condition affecting the pancreas, such as autoimmune diabetes or LADA (latent autoimmune diabetes in adults) — only under medical supervision.
- This is the important one for most people. Pancragen may increase your sensitivity to insulin, to **metformin** (the standard first-line diabetes tablet), to GLP medications such as semaglutide, and to **SGLT2 inhibitors** (another class of diabetes drug, with names ending in "-flozin"). Increased sensitivity means those drugs hit harder than usual, and with blood sugar medicines that means the risk of going too low. If you take any of them, this needs a doctor's involvement and blood sugar monitoring before you start, not after.
- Take care when combining with immune-acting compounds such as Thymosin Alpha-1, Vilon, and LL-37 — the combination may temporarily heighten immune sensitivity.
- Talk to a doctor before starting, and go through your full medication list with them.
- Absolute: pregnancy and lactation; severe acute pancreatitis; active pancreatic cancer.
- Under medical supervision only, as a separate stated category: uncontrolled diabetes mellitus, especially type 1; renal or hepatic failure; pancreatic autoimmune conditions including autoimmune diabetes and LADA.
- Glucose-lowering therapy: increased sensitivity to insulin, metformin, GLP medications, and SGLT2 inhibitors is stated. Hypoglycaemia is the foreseeable consequence of adding an insulin-sensitising agent to established glucose-lowering therapy, and no monitoring guidance, dose-adjustment advice, or specific hypoglycaemia warning has been established. This is the most actionable item here and it is stated only as an interaction.
- Immune-acting compounds (Thymosin Alpha-1, Vilon, LL-37): combination may temporarily heighten immune sensitivity.
- No glucose monitoring parameters have been established, despite the metabolic claims and the stated potentiation of four glucose-lowering drug classes.
Side effects
- Temporary tiredness or weakness, described as occurring during metabolic adjustment.
- A reaction where you inject — redness, swelling, or itching.
- Headache.
- Light-headedness.
- Mild stomach and gut upset — nausea, bloating, or indigestion.
- Swings in blood sugar during the first part of the course. Take this seriously if you are on any blood sugar medication: light-headedness, weakness, and fatigue are also the early signs of blood sugar dropping too low, so three of the items on this list overlap with that.
- Rarely, temporary signs of the immune system being stirred up — a general feeling of being unwell, or a fever.
- Temporary fatigue or weakness, attributed to metabolic adjustment.
- Injection site reaction: erythema, swelling, and/or pruritus.
- Headache.
- Light-headedness.
- Mild gastrointestinal upset: nausea, bloating, indigestion.
- Fluctuations in blood glucose during the initial dosing period. Note the symptomatic overlap — fatigue, weakness, and light-headedness are also early hypoglycaemic symptoms, so three items on this list are not distinguishable from hypoglycaemia on presentation. Combined with the stated potentiation of insulin, metformin, GLP agents, and SGLT2 inhibitors, that makes glucose monitoring the obvious requirement, even though it has not been formally specified.
- Rare: temporary immune activation or modulation symptoms — malaise, fever.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Named as a caution rather than a recommendation. Combining Pancragen with Thymosin Alpha-1 may temporarily heighten immune sensitivity.
Named in the interaction section as one of three immune-acting compounds whose combination may temporarily heighten immune sensitivity. Framed as a caution, not a protocol; no combined schedule or monitoring guidance is offered.
Named in the same caution as Thymosin Alpha-1 — it is one of the immune-acting compounds that may temporarily heighten immune sensitivity when combined with Pancragen. Vilon is a thymus-derived bioregulator, and it has its own page on this site.
Named alongside Thymosin Alpha-1 and LL-37 in the interaction section. Vilon is the site's thymus-derived dipeptide bioregulator, so the immune-sensitivity caution applies on shared ground. Cautionary, not a recommended pairing.
The third compound named in the same caution. Combining it with Pancragen may temporarily heighten immune sensitivity.
The third of the three immune-acting compounds named in the interaction section. Same caution, same absence of combined guidance.
Named from the other direction. The Cardiogen entry on this site says that combining it with metabolic bioregulators such as Pancragen may increase the overall effect on the body, and that the doses therefore need balancing.
Cross-referenced from the Cardiogen entry on this site, which names Pancragen specifically as a metabolic bioregulator whose combination may enhance systemic benefit and require dose balancing. The caution originates in the Cardiogen entry.
Dosing figures have been reviewed and units are recomputed from the stated protocol.